2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Practice Models, Quality Improvement, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2458 Fractionated myeloablative busulfan and fludarabine (f-BF) conditioning produces low relapse and encouraging survival in myelofibrosis

Uday Popat, MD, MBA, Rima M. Saliba, PhD2, Jeremy Ramdial, MD3, Portia Smallbone, MBBS (Hons), FRACP, FRCPA4, Samer A Srour, MB ChB, MS5, Crystal L Carmicheal6, Betul Oran, MD7, George Chen, MD8, Gheath Alatrash, PhD9, Jitesh Kawedia, BPharm10, Gabriela Rondon, MD11, Muzaffar Qazilbash, MD12, Partow Kebriaei, MD13, Warren Fingrut, MD, MPH14, Yosra M. Aljawai, MD MS15, Rohtesh Mehta, MD, MPH16, Chitra Hosing, MD17, Amin Alousi, MD18, Qaiser Bashir, MD19, David Marin20, Yago Nieto, MD, Ph.D21, Naveen Pemmaraju, MD22, Prithviraj Bose, MD23, Issa F. Khouri, MD24, Richard Champlin25, Elizabeth Shpall, MD26
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
24 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background

Allogeneic hematopoietic cell transplantation (alloHCT) remains the only curative treatment for myelofibrosis (MF). Current practice favors RIC because of patient age; however, relapse remains the dominant cause of treatment failure. Although conventional myeloablative conditioning (MAC) reduces relapse, its broader use has been limited by higher non-relapse mortality (NRM). We previously developed a pharmacokinetically guided fractionated busulfan platform that delivers myeloablative busulfan over three weeks, reducing regimen-related toxicity and non-relapse mortality while maintaining disease control. Combined with post-transplant cyclophosphamide (PTCy), this strategy has demonstrated low NRM and relapse across myeloid malignancies. Here, we evaluated the efficacy and safety of myeloablative fractionated busulfan and fludarabine (f-BF) in patients with MF.

Methods

We analyzed consecutive patients with intermediate- or high-risk MF who underwent alloHCT between July 2017 and May 2025 using f-BF conditioning. Patients received busulfan 80 mg/m² on days −20 and −13 (outpatient), followed by fludarabine 40 mg/m² and pharmacokinetically targeted busulfan on days −6 through −3 to achieve a cumulative exposure of 20,000 ±12% μmol·min/L. GVHD prophylaxis consisted of PTCy and tacrolimus with or without mycophenolate mofetil.

Results

Seventy patients underwent alloHCT. Median age was 62 years (range, 33–76; IQR, 57–69), including 32 (46%) patients aged >65 years. Fifty-nine percent had primary MF and 41% had post-essential thrombocythemia or post-polycythemia vera MF. Disease risk by DIPSS-Plus was intermediate-1 in 16%, intermediate-2 in 56%, and high-risk in 29%. Half of the patients had an HCT-CI ≥3, 28% had a Karnofsky Performance Status <90, and 10% had massive splenomegaly (≥15 cm below the costal margin). Median interval between diagnosis and transplant was 48 (4-374) months. Median CD34 cell dose infused was 6.4 X 106/kg (2.2-22). Fifty nine (84%) received a Jak inhibitor before transplantation. Donors were matched related (34%) or 10/10 matched unrelated (66%), and peripheral blood stem cells were used in 99% of transplants.

One patient experienced primary graft. Median neutrophil and platelet engraftment occurred at 18 (IQR, 16–21) and 34 (IQR, 23–58) days, respectively. At day 30 median T cell chimerism was 95% (25-100) and myeloid chimerism was 100% (98-100)

After a median follow-up of 24 months (IQR, 14–75), median progression-free survival (PFS) and overall survival (OS) had not been reached. Two-year OS and PFS were 78% and 75%, respectively. The 2-year cumulative incidence of relapse was only 6%, while NRM was 17%. Six-month cumulative incidences of grade II–IV and grade III–IV acute GVHD were 38% and 3%, respectively, and the 2-year cumulative incidence of chronic GVHD was 26%.

On multivariable analysis, HCT-CI >4 was the only independent predictor of inferior PFS (HR 2.8, P=0.015) and OS (HR 4.4, P=0.008). Patients with HCT-CI ≤4 achieved excellent outcomes, with 2-year OS and PFS of 85% and 81%, respectively.

Conclusions

Myeloablative fractionated busulfan and fludarabine (f-BF) achieved excellent disease control with a remarkably low 2-year relapse rate of only 6% while maintaining acceptable non-relapse mortality, despite inclusion of older patients (up to 76 years) and those with significant comorbidities. These findings support fractionated busulfan as a reduced-toxicity myeloablative conditioning platform that may safely extend the benefits of myeloablative transplantation to patients who would otherwise receive reduced-intensity conditioning. Prospective studies comparing f-BF with conventional RIC regimens in myelofibrosis are warranted.

Uday Popat, MD, MBA: Incyte - Research Funding; Abbvie - Research Funding; Novartis - Research Funding; TScan - Research Funding; Bayer - Research Funding; Daiichi Sankyo - Consultancy (Includes expert testimony); Illuminate Health - Consultancy (Includes expert testimony)